BL-1230

BL-1230 is a **selective agonist of the cannabinoid receptor type 2 (CB2R)**, developed as a small molecule pharmaceutical drug for the potential treatment of dry eye syndrome. The compound works by specifically activating the CB2 receptor, which is primarily expressed in immune cells and is known to modulate inflammation and immune responses without the psychotropic effects associated with cannabinoid receptor type 1 (CB1R). Its development was led initially by The Hebrew University of Jerusalem, then licensed to BioLineRx, and later partnered with Novartis for further advancement. The global highest R&D status for BL-1230 is "Discontinued", meaning clinical development was halted and it will not reach the market in its originally intended indication[1][3].